Short Interest in Bayer Aktiengesellschaft (OTCMKTS:BAYRY) Decreases By 80.8%

Bayer Aktiengesellschaft (OTCMKTS:BAYRY) was the target of a significant decline in short interest during the month of August. As of August 31st, there was short interest totaling 127,301 shares, a decline of 80.8% from the August 15th total of 661,820 shares. Based on an average trading volume of 724,767 shares, the short-interest ratio is presently 0.2 days. Currently, 0.0% of the company’s shares are short sold.

Bayer Aktiengesellschaft Stock Performance

Shares of Bayer Aktiengesellschaft stock opened at $13.95 on Friday. The company has a current ratio of 1.04, a quick ratio of 0.67 and a debt-to-equity ratio of 1.05. The stock’s fifty day moving average price is $14.00 and its 200-day moving average price is $12.27. The firm has a market cap of $54.82 billion, a P/E ratio of -27.35, a P/E/G ratio of 2.10 and a beta of 0.56. Bayer Aktiengesellschaft has a 12 month low of $7.48 and a 12 month high of $15.23.

Bayer Aktiengesellschaft (OTCMKTS:BAYRY) last released its quarterly earnings data on Tuesday, August 4th. The company reported $0.29 earnings per share for the quarter, topping analysts’ consensus estimates of $0.23 by $0.06. Bayer Aktiengesellschaft had a negative net margin of 3.80% and a positive return on equity of 16.77%. The company had revenue of $12.53 billion during the quarter, compared to analyst estimates of $12.31 billion. Bayer Aktiengesellschaft has set its FY 2026 guidance at 1.200-1.346 EPS. On average, equities research analysts expect that Bayer Aktiengesellschaft will post 1.28 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several equities research analysts have recently issued reports on BAYRY shares. DZ Bank upgraded shares of Bayer Aktiengesellschaft from a “hold” rating to a “strong-buy” rating in a report on Tuesday, May 19th. Zacks Research upgraded shares of Bayer Aktiengesellschaft from a “hold” rating to a “strong-buy” rating in a report on Friday, July 10th. Deutsche Bank Aktiengesellschaft raised shares of Bayer Aktiengesellschaft from a “hold” rating to a “buy” rating in a research report on Thursday, July 2nd. Finally, Jefferies Financial Group upgraded Bayer Aktiengesellschaft to a “hold” rating in a research report on Friday, May 29th. Two equities research analysts have rated the stock with a Strong Buy rating, five have given a Buy rating and one has assigned a Hold rating to the company. According to data from MarketBeat.com, the company has an average rating of “Buy”.

About Bayer Aktiengesellschaft

Bayer Aktiengesellschaft is a Germany-based life sciences company headquartered in Leverkusen. Founded in 1863, the company develops and markets products in healthcare and agriculture and serves customers in markets around the world. Bayer’s American depositary shares trade over the counter under the symbol BAYRY.

The company operates through three principal areas: Pharmaceuticals, Consumer Health and Crop Science. Its Pharmaceuticals business develops prescription medicines in areas such as cardiovascular disease, women’s health, oncology, neurology and specialty therapeutics.